Rapid Micro Biosystems Revenue and Competitors

Boston, MA USA

Location

$358.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Rapid Micro Biosystems's estimated annual revenue is currently $23.3M per year.(i)
  • Rapid Micro Biosystems received $60.0M in venture funding in May 2018.
  • Rapid Micro Biosystems's estimated revenue per employee is $105,727
  • Rapid Micro Biosystems's total funding is $358.4M.
  • Rapid Micro Biosystems's current valuation is $301M. (January 2022)

Employee Data

  • Rapid Micro Biosystems has 220 Employees.(i)
  • Rapid Micro Biosystems grew their employee count by 5% last year.

Rapid Micro Biosystems's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
SVP and General CounselReveal Email/Phone
3
VP, Quality and Regulatory AffairsReveal Email/Phone
4
VP OperationsReveal Email/Phone
5
Director Continuous ImprovementReveal Email/Phone
6
Director Global Sales OperationsReveal Email/Phone
7
Sr. Director Financial Planning & AnalysisReveal Email/Phone
8
Chief Human Resources OfficerReveal Email/Phone
9
Director, Total Rewards, HRIS & AnalyticsReveal Email/Phone
10
Senior Director, Supply Chain ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Rapid Micro Biosystems?

Rapid Micro Biosystems creates innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company's Growth Directthe first and only growth-based system to automate compendial testingdetects contamination more quickly, delivering compelling economic benefits to manufacturers while improving their quality control (QC) process. Growth Direct addresses all key microbial QC applications and fits with current regulatory practices, a critical accelerator for adoption. Automated, accelerated analysis eliminates error-prone manual steps and saves labor. Rapid detection of contamination enables manufacturers to reduce inventory carrying costs, shorten manufacturing cycles, and reduce product losses, delivering significant cost savings and increased operational efficiency. Rapid Micro Biosystems' proprietary technology is based on the detection of natural autofluorescence. The inventors of the core principle, efficient blue light-emitting diodes, which has enabled bright and energy-saving white light sources, won the Nobel Prize in Physics. Rapid Micro Biosystems is headquartered in Lowell, Massachusetts, with operations in Lowell and Freising, Germany.

keywords:Biotechnology,Hardware,Hardware Peripherals,Healthcare,Human Resources Hr,Medical Diagnostics,Pharmaceuticals

$358.4M

Total Funding

220

Number of Employees

$23.3M

Revenue (est)

5%

Employee Growth %

$301M

Valuation

N/A

Accelerator

Rapid Micro Biosystems News

2022-04-20 - Asahi Kasei acquires Bionova and its shiny new California site

In 2020, it contributed to Rapid Micro Biosystems' $120 million financing round, and in 2019, the Tokoyo-based company purchased the...

2022-04-17 - Short Interest in Rapid Micro Biosystems, Inc. (NASDAQ:RPID ...

Rapid Micro Biosystems, Inc provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology,...

2022-03-22 - Rapid Micro Biosystems Reports Fourth Quarter and Full Year ...

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the...

2021-07-20 - Rapid Micro Biosystems : Longitude Capital Raises Inaugural Opportunities Fund with $135 Million to Invest in Breakout Healthcare Companies

- Longitude Prime Fund makes first investment in IPO of Rapid Micro Biosystems, the industry leading automated quality-control platform for pharmaceutical manufacturing - MENLO PARK, Calif., GREENWICH, Conn., and BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Longitude Capital, a leading healthcare ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M2436%N/A
#2
$15M250N/AN/A
#3
$99.1M2795%N/A
#4
$128M3534%N/A
#5
$15M37321%N/A

Rapid Micro Biosystems Funding

DateAmountRoundLead InvestorsReference
2005-08-15$4.1MSecondNtl Institute of Allergy and IArticle
2009-07-09$18.6MAArticle
2013-06-27$32.6MBLongitude Capital, TPG BiotechArticle
2014-04-14$6.0MUndisclosedArticle
2014-12-16$19.0MUndisclosedGE CapitalArticle
2015-04-30$25.0MUndisclosedHepalink USA Inc.Article
2018-05-03$60.0MUndisclosedBain CapitalArticle